Search Weight Loss Topics:

Page 55«..1020..54555657..6070..»

Home » Long Term Weight Loss » Page 55

Male Aesthetic Plastic Surgery

PITTSBURGH (PRWEB) November 03, 2020

World renowned innovative University of Pittsburgh Clinical Professor of Plastic Surgery, Dennis J Hurwitz, MD has recently published updates on his unique body contouring surgery of the male. The prestigious International plastic surgery Journal, Aesthetic Plastic Surgery, recognized Dr. Hurwitzs 2015 article Enhancing Masculine Features After Massive Weight Loss as one of the most highly referenced articles in the journals 50-year history. This open access article may be downloaded by searching Hurwitz D, Enhancing Masculine Features after Massive Weight Loss, Aesth Plast Surg. 2016. 40:2; 245-255. The journal republished it in in August 2020, followed by an editorial update in Aesth Plast Surg. 2020; 44, 1252-1257. His unique Boomerang pattern correction of gynecomastia remains a favorite approach to difficult sagging gynecomastia correction. The Boomerang procedure nicely compliments Oblique Flankplasty with Lipoabdominoplasty over one or two stages. New techniques using high definition liposculpture with Pectoralis muscle fat grafting and BodyTite skin tightening has become the mainstay of the more common moderate presentations of gynecomastia in muscular males with poor definition.

Then in September 2020, the long awaited first plastic surgery textbook exclusively on males was published. Editor of Male Aesthetic Plastic Surgery, Theime 2020, D.S. Steinbrech selected Dr. Hurwitz to write chapter 22 on Boomerang Excision Pattern Correction of Gynecomastia and chapter 40 on Body Lift after Massive Weight Loss in Men. These step by step surgical atlas presentations with technique videos should help popularize his techniques and improve results by other surgeons. Early reviews of the textbook have praised its encyclopedic presentation from the best know plastic surgeon contributors of today.

This COVIID-19 era of social distancing has not slowed down Dr. Hurwitz world-wide scientific presentations at authoritative American and international conferences. Through video conferencing, Dr. Hurwitz continues to be invited to present his artistry in body contouring surgery. On May 18, 2020 Dr. Hurwitz was honored by the So Paulo division of the Brazilian Society of Plastic Surgery as an annual conference keynote speaker on the Centrality of Oblique Flankplasty and lipoabdominoplasty. Similarly, he has presented at the annual meeting of the of PAP, Pakistan Association of Plastic Surgeons, and Saudi Arabian Society of Plastic Surgeons, July 18, 2020. Also, he spoke for an hour for surgical residents of Britains United Kingdom series of webinars for trainees September 24. During the on-demand session of the American Society of Plastic Surgeon PSTM2020 October 12, Hurwitz was the guest moderator for Vector base liposculpture for men. On Thursday, 11/5/20, he will present a 90-minute treatise on his evolution of body contouring surgery to the present Oblique Flankplasty at the Georgetown Department of Plastic Surgery Virtual Grand Round Lecture Series, which include prestigious Departments at Universities of Michigan and Pennsylvania.

The common theme of these presentations is his evolving experience using the combination of lipoabdominoplasty with his unique lower body lift operation, the Oblique Flankplasty (OFLA). He described the centrality of this operative combination to the reshaping of the entire torso of individuals who suffer loose skin and poor body shape after weight loss pregnancy and/or aging. Through photographs and video presentations of both men and woman that included before-and-after results he convincingly taught the application of his still evolving approach to excellent body contouring. Dr. Hurwitz explains how total body lift surgery came to happen and what have been the scientific, social and patient highlights of cultivating body contouring specialty over the past 22 years. He anticipates that the brilliant but impressionable residents and medical students will be inspired to take a similar path towards developing and advancing their specialty interest in plastic surgery. They need to understand long term goals, the search for excellence, unraveling deficiencies and realizing the length of time, it takes to make a difference and the considerable effort in preparation of lectures, traveling and manuscripts and book chapters. The satisfactions and rewards will be self-evident to those who attend. Dr. Hurwitz is clear that this approach to the practice of plastic surgery has not only brought achievements in innovation, but the best possible care for his patients one at a time, day in and day out. For those who wish to view the August 2019 recorded similar presentation for an ICOPLAST international webinar for plastic surgeons please search lower body lift by Dennis Hurwitz on Vimeo.

Recently, plastic surgeon, UNLV adjunct assistant professor, Armando A. Davila, M.D. has joined the Hurwitz Center for Plastic Surgery working side by side with Dr. Hurwitz and making his unique contributions to patient care and clinical research. For more information about achieving an optimal figure and what treatments best suit your needs, contact the Hurwitz Center for Plastic Surgery, http://www.hurwitzcenter.com. The practice can be reached directly using the information provided below.

The Hurwitz Center for Plastic Surgery3109 Forbes Ave., Suite 500Pittsburgh, Pennsylvania 15213(412) 802-6100

Share article on social media or email:

Continue reading here:
Dr. Dennis J. Hurwitz publishes techniques and artistic long-term results in male body contouring - PR Web

Cushings disease, or more correctly, pars pituitary intermedia dysfunction (PPID), is a metabolic condition that affects middle-aged and older horses.

In PPID, the pituitary gland in the brain produces an excessive amount of the hormone ACTH, which stimulates the production of large amounts of cortisol, the stress hormone. Cortisol has many negative effects in the body, including suppression of the immune system and insulin resistance. There is currently no cure for PPID in horses; instead, it must be managed.

Signs of PPID include weight loss, loss of muscle (especially along the topline), a long hair coat that does not shed out in the summer, laminitis and chronic infections that seem to recur or linger (e.g. hoof abscesses). Generalized obesity is not a typical sign of PPID; however, horses may have fat deposits in certain areas (e.g. over the tail, head, neck and/or shoulder).

In some cases, a veterinarian can diagnose PPID based on the clinical signs alone. In other horses, the combination of clinical signs plus a blood test that measures the ACTH level in the body is needed for diagnosis.

A veterinarian may choose to measure insulin and glucose because these markers tend to be elevated in horses with PPID, and some horses may suffer from another condition known as Equine Metabolic Syndrome. In instances where the ACTH test result is inconclusive, or in the early stages of PPID, a veterinarian may need to perform a thyrotropin-releasing hormone stimulation test.

ACTH levels vary throughout the year in all horses, which can complicate the interpretation of blood tests for PPID. Most normal horses show an increase in ACTH in the fall; however, the magnitude of this increase is much higher in horses with PPID compared to normal horses. Therefore, a veterinarian may choose to test for PPID in the fall.

The main treatment for a horse with PPID is daily administration of a medication known as pergolide. In the U.S., there is currently one FDA-approved product. When given appropriately, an initial response can be seen in as little as 30 days and long-term improvements will be seen over the period of one to twelve months.

Your veterinarian will recommend to periodically measure your horses ACTH to adjust the horses dose as needed. There are other management considerations for horses with PPID, including dentistry, body condition, body weight, nutrition and parasite control.

Read this article:
Diagnosing and managing a horse with Cushing's Disease - AberdeenNews.com

Introduction and Scope: Global Weight Loss and Diet Management Products and Services MarketBased on highly decisive data unravelling approach braced by highly professional researchers and analysts in our teams, the Global Weight Loss and Diet Management Products and Services Market is expected to nail a bullish growth through the growth span, 2019-25.

The report is poised to include definitive details of the market forces, growth catalysts that collectively influence lucrative growth returns. The market with his current growth prognosis as well as an eventful historical success rate is likely to accrue high end investment returns, while also maintaining a decent CAGR percentage through the growth years considered in the report.

which market players and aspiring new entrants may witness seamless entry.AHD InternationalAtkins NutritionalsBio-SynergyBody-SolidBrunswickConagra FoodsGlaxosmithklineKelloggKraft FoodsMedifastNautilusNestleNutrasweetNutrisystemPepsicoQuaker OatsSkinny NutritionalStreamline FoodsTate And LyleCoca-ColaHersheyUnileverVivusVlcc GroupWeight WatcherWellness International

The report in its modest attempt to unfurl notable market developments successfully includes details on revenue predictions, sales performance profit margin as well as market specific segmentation and vendor profiles who continue to hold tangible lead despite unprecedented challenges and catastrophes.

Identifying Growth Influencers and Potential ThreatsThis well researched report presentation delving into global Weight Loss and Diet Management Products and Services market highlights some of themost dominant trends and other market specific influencers that entail positive and negative implications on growth possibilities.

Find full report and TOC here: @ https://www.orbismarketreports.com/global-weight-loss-and-diet-management-products-and-services-market-growth-analysis-by-trends-and-forecast-2019-2025?utm_source=Puja

The report minutely assesses key developments trends besides also identifying growth deterrents and constraints that shrink growth possibilities. Additional market specific developments highlighting COVID-19 outbreak and its subsequent implications on holistic growth trajectory of the Weight Loss and Diet Management Products and Services market have been thoroughly assessed to gauge into current as well as future implications of the pandemic, affecting businesses and growth trends significantly.

The market is roughly segregated into: Segmentation by TypeMealsBeveragesSupplements

Segmentation by ApplicationWeight Loss SurgeryMDsHospitals/Clinic ProgramsRx Diet DrugsBariatriciansVLCD Programs

Geographical Landscape global Weight Loss and Diet Management Products and Services market: Details for Consideration For superlative reader awareness and informed business decisions, this report section actively bifurcates the overall market into key geographical pockets comprising North America, Europe, Asia-Pacific, Southeast Asia, Middle East and Africa, South America.

In its subsequent sections, the report also includes vital details about the growth performance, revenue generation trends as well as vendor activities across specific geographical hubs and futuristic growth possibilities in the areas.

Crucial information on revenue generation trends and growth rate projections have also been well included in this report.

COVID-19 Impact Analysis The overall status of the Weight Loss and Diet Management Products and Services market with pandemic outrage has been mindfully assessed and accurate predictions have also been made to aid futuristic growth projections

Changing parameters across supply-chain dynamics have been addressed in the report.

Both long term and short-term market growth implications accrued by affected business developments with pandemic looming large.

Primary Purpose of the Report The report follows a top down investigative approach to unravel forecast projections The report presents a thorough investigative study of the Weight Loss and Diet Management Products and Services market to assist and guide profitable business discretion This high-end research report representation on the Weight Loss and Diet Management Products and Services market is fundamentally aimed to unravel developments such as supply and demand scenario Further, the report scouts further analysis to identify and group the eventful developments, sectioning them in fragments and categories to direct profit ventures in the Weight Loss and Diet Management Products and Services market, also aiding market participants business discretion

Relevant details on prevalent market competition and rising intensity with inclusion of new market players also find ample mention in the report to evoke wise comprehension and appropriate growth related business strategies, favoring strong competitive edge. Details on technological innovation, and inputs developments, commercial agreements have all been touched upon in this illustrative research report on the Weight Loss and Diet Management Products and Services market.

Do You Have Any Query or Specific Requirement? Ask Our Industry [emailprotected] https://www.orbismarketreports.com/enquiry-before-buying/86384?utm_source=Puja

Subsequently in the report, readers are also well enlightened about the current scenario in the competitive landscape highlighting key vendors and their steady growth journey through the forecast span. Details pertaining to company performance, portfolio developments as well as profit returns have been discussed alongside SWOT analysis.

Looking for provoking fruitful enterprise relationships with you!

About Us : With unfailing market gauging skills, has been excelling in curating tailored business intelligence data across industry verticals. Constantly thriving to expand our skill development, our strength lies in dedicated intellectuals with dynamic problem solving intent, ever willing to mold boundaries to scale heights in market interpretation.

Contact Us : Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155

Read the original post:
Global Weight Loss and Diet Management Products and Services Market 2025 Expected to Reach Highest CAGR During COVID 19 crisis : AHD International,...

Weight Loss Programs Market Reports provide results and potential opportunities and challenges to future Weight Loss Programs industry growth. Weight Loss Programs market research reports offers five-year revenue forecasts through 2024 within key segments of the Weight Loss Programs industry.

The Global Weight Loss Programs Market is poised to grow strong during the forecast period 2017 to 2026. Weight Loss Programs market is the definitive study of the global Weight Loss Programs industry. The report content includes technology, industry drivers, geographic trends, market statistics, market forecasts, producers, and raw material/equipment suppliers.

If you are planning to invest into new products or trying to understand this growing market, this report is your starting point.Get Exclusive Sample PDF Copy:https://inforgrowth.com/sample-request/6477711/weight-loss-programs-market

The Weight Loss Programs industry study concludes with a list of leading companies/suppliers operating in this industry at different stages of the value chain.

Major Classifications of Weight Loss Programs Market:

Major Key players covered in this report:

By Product Type:

By Applications:

HALLOWEEN OFFER: Get up-to 30% Extra Discount for this Exclusive Gene Synthesis Service Market Report,https://inforgrowth.com/discount/6477711/weight-loss-programs-market

The Weight Loss Programs market research report provides a concise and clear overview of this complex and often dynamic industry. The report dives into the trends in the specialty Weight Loss Programs industry by looking at the market from a regional perspective, application perspective, and materials point of view. As a market with significant growth potential, we look not only at the market today, but also at how it will develop over the next three years and the trends and developments that will drive growth.

Weight Loss Programs Market Overview:

Impact of COVID-19:Weight Loss Programs Market report analyses the impact of Coronavirus (COVID-19) on the Weight Loss Programs industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Weight Loss Programs market in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Get Sample Table of Content PDF of COVID-19/CoronaVirus Impact Analysis of Weight Loss Programs Market 2020.https://inforgrowth.com/CovidImpact-Request/6477711/weight-loss-programs-market

Why Buy This Weight Loss Programs Market Report?

Get accurate data and strategic insights on the worldwide Weight Loss Programs market & key players.

What is the market share and respective growth rate between the various application segments? Between developed and emerging economic regions?

Apprehend the magnitude of latest manufacturing trends (future trends, upcoming technologies etc).

As global capacity for and production in Weight Loss Programs market to increase, which geographic regions will have the largest volume and highest growth rates for Weight Loss Programs consumption?

For investors & private equity firms: identify the best companies to invest in.

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898

Read the original:
Weight Loss Programs Market 2020: Potential Growth, Challenges, and Know the Companies List Could Potentially Benefit or Loose out From the Impact of...

EAST HANOVER, N.J., Nov. 5, 2020 /PRNewswire/ -- Novartis, a leader in rheumatology and immuno-dermatology, today announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial, which demonstrated the significant treatment response of Cosentyx (secukinumab) on synovitis (joint lining inflammation) in psoriatic arthritis (PsA) versus placebo. Synovitis was assessed using an advanced and sensitive imaging technique called Power Doppler ultrasonography (PDUS). These data are being presented at the American College of Rheumatology (ACR) All-Virtual Annual Meeting, November 5-9, 2020.

"Psoriatic arthritis can have a significant impact on a patient's joints. Joint lining inflammation, also known as synovitis, if left untreated, can cause pain to worsen, joint damage and may decrease physical function," said Dr. Maria A. D'Agostino, Professor of Rheumatology at the Catholic University of Rome. "These data are highly encouraging, showing Cosentyx can significantly reduce synovitis at Week 12 versus placebo with results seen as early as Week 1, and that ultrasound is a sensitive and objective tool to monitor joint inflammation in PsA patients."

The use of a standardized ultrasound synovitis score (GLOESS) as the primary endpoint showed objectively the significant benefit of Cosentyx versus placebo on synovitis at Week 12 with an early improvement observed from Week one. Treatment with Cosentyx also significantly improved key secondary endpoints versus placebo, including ACR20 (68% vs 34%, respectively), ACR50 (46% vs 9%, respectively) and enthesitis (mean change from baseline in Spondyloarthritis Research Consortium of Canada enthesitis index score [SPARCC] of -2.4 vs -1.7 respectively)1. The safety profile of Cosentyx through 12 weeks was consistent with previous studies1.

Novartis anticipates disclosing full 24-week data from the ongoing ULTIMATE trial at the European League Against Rheumatism (EULAR) annual meeting in 2021 and final analysis at ACR 2021.

"As a strong believer in the diagnostic and treatment monitoring benefits of ultrasound, this first large randomized double-blind placebo-controlled clinical trial in PsA with an ultrasonographic primary endpoint is incredibly exciting. The ability to use a sensitive imaging technique to assess synovitis and enthesitis in PsA represents a breakthrough in how we conceptualize treatment goals," said Dr. Catherine Bakewell of Intermountain Medical Group in Salt Lake City, UT and an investigator in the ULTIMATE study. "In addition to other measures, PDUS helps to provide earlier insight into treatment response and that patients are more effectively treated across multiple domains of this heterogeneous psoriatic disease spectrum."

PsA is a complex disease with multiple manifestations driving patient symptoms3,4. In PsA, synovitis may lead to joint damage and if left untreated, the joint damage can be irreversible5,6. In addition to reducing synovitis, Cosentyx has been proven to provide long-lasting inhibition of radiographic progression in PsA, limiting joint damage and helping to improve outcomes for patients with this debilitating condition7,8.

About Psoriatic Arthritis (PsA)PsA is estimated to affect up to 50 million people worldwide9,10. It is part of a family of life-long inflammatory diseases (spondyloarthritis) that target the joints and is closely associated with psoriasis10. Up to 40% of patients with psoriasis may develop PsA10. Symptoms of PsA include joint pain and stiffness, skin and nail psoriasis, swollen toes and fingers, persistent painful swelling of the tendons and irreversible joint damage10.

About ULTIMATE ULTIMATE is the first ongoing 52-week double-blind, placebo-controlled Phase IIIb study using ultrasound to assess time-course of response of Cosentyx on synovitis in psoriatic arthritis. The study enrolled 166 adult biologic-nave patients with active Psoriatic arthritis. Patients were randomized (1:1) to receive either secukinumab (300-mg or 150-mg according to severity of skin disease) or placebo weekly for a month with treatment starting at Week 4, followed by a once-a-month dose for the next 11 months.

The primary endpoint is the difference in mean change from baseline to Week 12 between secukinumab and placebo in Global Omeract-European League Against Rheumatism Ultrasound Synovitis Score (GLOESS). GLOESS is a standardized composite score that has shown to be sensitive to change and able to detect and score synovitis11. Secondary endpoints include ACR20, ACR50 and change in Spondyloarthritis Research Consortium of Canada (SPARCC) enthesitis index from baseline to Week 12 compared with placebo.

ACR20 and ACR50 are composite measures defined as both improvement of 20% or 50% in the number of tender and number of swollen joints, and a 20% or 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, Health Assessment Questionnaire, visual analog pain scale and erythrocyte sedimentation rate or C-reactive protein12. The SPARCC enthesitis index is a validated clinical tool for evaluation of enthesitis13,14.

About Cosentyx (secukinumab)Cosentyx is the first and only fully-human biologic that directly inhibits interleukin-17A (IL-17A), an important cytokine involved in the inflammation and development of psoriatic arthritis (PsA), moderate to severe plaque psoriasis (PsO), ankylosing spondylitis (AS) and nr-axSpA15,16. Cosentyx has been studied clinically for more than 13 years. The medicine is backed by robust investigational evidence, including five years of clinical data supporting long-term safety and efficacy across moderate to severe plaque psoriasis (PsO), psoriatic arthritis (PsA) and ankylosing spondylitis (AS)17-22,23. These data strengthen the unique position of Cosentyx as a comprehensive treatment across axial spondyloarthritis, psoriatic arthritis and psoriatic disease, supported by more than 400,000 patients treated worldwide since launch2,23,24.

IMPORTANT SAFETY INFORMATIONDo not use COSENTYX if you have had a severe allergic reaction to secukinumab or any of the other ingredients in COSENTYX. See the Medication Guide for a complete list of ingredients.

COSENTYX is a medicine that affects your immune system. COSENTYX may increase your risk of having serious side effects such as:

InfectionsCOSENTYX may lower the ability of your immune system to fight infections and may increase your risk of infections.

Before starting COSENTYX, tell your doctor if you:

After starting COSENTYX, call your doctor right away if you have any signs of infection listed above. Do not use COSENTYX if you have any signs of infection unless you are instructed to by your doctor.

Inflammatory Bowel DiseaseNew cases of inflammatory bowel disease or "flare-ups" can happen with COSENTYX, and can sometimes be serious. If you have inflammatory bowel disease (ulcerative colitis or Crohn's disease), tell your doctor if you have worsening disease symptoms during treatment with COSENTYX or develop new symptoms of stomach pain or diarrhea.

Serious Allergic ReactionsSerious allergic reactions can occur. Get emergency medical help right away if you get any of the following symptoms: feeling faint; swelling of your face, eyelids, lips, mouth, tongue, or throat; trouble breathing or throat tightness; chest tightness; or skin rash. If you have a severe allergic reaction, do not give another injection of COSENTYX.

Before starting COSENTYX, tell your doctor if you:

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Know the medicines you take. Keep a list of your medicines to show your doctor and pharmacist when you get a new medicine.

How should I use COSENTYX?See the detailed Instructions for Use that comes with your COSENTYX for information on how to prepare and inject a dose of COSENTYX, and how to properly throw away (dispose of) used COSENTYX Sensoready pens and prefilled syringes.

The most common side effects of COSENTYX include: cold symptoms, diarrhea, and upper respiratory infections. These are not all of the possible side effects of COSENTYX. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information, including Medication Guide.

DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About NovartisLocated in East Hanover, NJ Novartis Pharmaceuticals Corporation an affiliate of Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis employs more than 15,000 people in the United States. For more information, please visit https://www.novartis.us.

Novartis and Novartis US is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews and @NovartisUS at https://twitter.com/NovartisUS.For Novartis multimedia content, please visit https://www.novartis.com/news/media-libraryFor questions about the site or required registration, please contact media.relations@novartis.com.

References

1.

D'Agostino MA, Schett G, Lpez-Rdz A, et al. Secukinumab significantly decreased joint synovitis measured by power Doppler ultrasonography in biologic nave patients with active psoriatic arthritis: primary (12-week) results from a randomized, placebo-controlled Phase III study. Abstract presented at the American College of Rheumatology (ACR) Convergence 2020: The ACR's All-Virtual Annual Meeting.

2.

Data on file. COSENTYX access. Novartis Pharmaceuticals Corp; July 2020.

3.

Ritchin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957-970.

4.

Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Rheumotol Ther. 2016;3(1):91-102.

5.

Van Kuijk A, Tak P. Synovitis in psoriatic arthritis: immunochemistry, comparisons with rheumatoid arthritis and effects of therapy. Curr Rheumatol Rep. 2011;13:353-359.

6.

Celis R, Cuervo A, Ramirez J, et al. Psoriatic synovitis: singularity and potential clinical implications. Frontiers in Medicine. 2019;6:1-7

7.

Mease P, van der Heijde D, Landew R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study Annals of the Rheumatic Diseases 2018;77:890-897.

8.

Van Der Heijde D, Mease PJ, Landewe R, et al. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology. 2020;59:13251334

9.

National Psoriasis Foundation. Psoriasis statistics. Available from: https://www.psoriasis.org/content/statistics. Last accessed: October 2020.

10.

Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74:423-441.

11.

D'Agostino MA, Terslev L, Aegerter P, et al. Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-Part 1: definition and development of a standardised, consensus-based scoring system. RMD Open. 2017;3:e000428.

12.

Eprovide. American College of Rheumatology 20/50/70 criteria (ACR20/50/70). Available from: https://eprovide.mapi-trust.org/instruments/american-college-of-rheumatology-20-50-70-criteria#:~:text=The%20ACR20%20is%20a%20composite,Health%20Assessment%20Questionnaire%20(HAQ)%5D%2C. Last accessed: October 2020.

13.

Maksymowych WP, Mallon C, Morrow S, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index. Ann Rheum Dis. 2009;68(6):948-953.

14.

Mease PJ, Van den Bosch F, Sieper J, Xia Y, Pangan AL, Song IH. Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. J Rheumatol. 2017 May;44(5):599-608.

15.

Novartis Europharm Limited. Cosentyx (secukinumab): Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx Last accessed: August 2019.

16.

Girolomoni G, et al. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 2012;167:717724.

17.

Data on file. CAIN457F2310 (MEASURE 2): 5 Year Report. Novartis Pharmaceuticals Corp; September 15, 2015.

18.

Data on file. Data Analysis Report: Study CAIN457A2302E1. Novartis Pharmaceuticals Corp; November 30, 2015.

19.

Data on file. CAIN457F2310 and CAIN457F2305 Summary of 5-Year Clinical Safety in (Ankylosing Spondylitis). Novartis Pharmaceuticals Corp; May 2019.

20.

Data on file. CAIN457F2312 (FUTURE 2): 5 Year- Interim Report. Novartis Pharmaceuticals Corp; May 2019.

21.

Data on file. CAIN457F2312 Data Analysis Report. Novartis Pharmaceuticals Corp; November 2008.

22.

Data on file. CAIN457F2310 (MEASURE 1 and 2): Pooled Safety Data. Novartis Pharmaceuticals Corp; July 23, 2018.

23.

Cosentyx [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2020.

24.

Data on file. AIN457A2102 Clinical Study Report. Novartis Pharmaceuticals Corp; December 2008.

View original content:http://www.prnewswire.com/news-releases/novartis-cosentyx-shows-early-synovitis-reduction-in-patients-with-psoriatic-arthritis-in-first-of-its-kind-study-301166845.html

SOURCE Novartis Pharmaceuticals Corporation

See original here:
Novartis Cosentyx shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study - BioSpace

Speaking to Express.co.uk, Bulk Powders ambassador Hayley Madigan shared her top weight training tips.

She said: Weight training has a vast range of positive benefits for women, not just physically but mentally too! Weight training loads a resistance to our muscles, which allows them to rebuild stronger.

Not only does weight training improve our muscle strength, it also strengthens our bones, joints, ligaments and tendons all vital for our long-term health.

Additional to these benefits, weight training can improve heart health and blood pressure, improving our fitness as well as strength.

READ MORE:Adam Woodyatt weight loss: EastEnders star made easy change to slim

For complete beginners, I recommend starting in either a group training environment (like a (virtual) class for example) or with a personal trainer (online or in person).

When you have the advice of an instructor or coach you will learn how to train correctly and safely, this will enable you to perfect your technique and lower any injury risk.

The weights area in a gym training environment can look and feel a little intimidating to newbies, so following a routine even from your favourite Instagrammer or YouTuber will give you the courage to try something new and hit the weights.

It is also best to start of using small weights regularity and build up to heavier ones as this will cause less strain on the muscles.

Protein is also great for weight loss as it reduces the hunger hormone and boosts several satiety hormones.

Hayley continued: There are many forms of weight training you can try, from CrossFit to Body Pump classes (or virtual classes) it isnt a one size fits all form of training and is highly versatile.

Depending on your goal, I would always recommend incorporating some kind of weight training, even if youre a long-distance runner or a Yogi, the benefits of weight training can improve your performance in pretty much every sport.

Full body training can be a brilliant way to maintain strength all over if you only train two-three times a week, then adding in body part splits like lower body and upper body training can be a great way to target the individual muscles if you train more often like four-six times a week.

Research suggests that weight lifting burns almost just fat which can help target those stubborn areas which may carry more fat.

The expert explains how weight training is also a great way to develop coordination, attention and memory.

She explained: All of these improvements to the cognitive part of your brain will relay over to your everyday living, including your studying or working life there is so much more to weight training than just improving muscle mass!

Original post:
How to exercise to lose weight and build muscle at the same time - Daily Express

This article was originally published here

Obes Surg. 2020 Oct 30. doi: 10.1007/s11695-020-05045-7. Online ahead of print.

ABSTRACT

PURPOSE: Bariatric surgery is the most effective treatment for severe obesity, but currently, only 1-2% of all eligible patients undergo surgery each year. This study examined which factors were associated with a patient receiving bariatric surgery after referral in a real-world healthcare setting.

MATERIALS AND METHODS: The current study used the baseline survey and electronic medical record (EMR) data from the Bariatric Experience Long Term (BELONG) study (n = 1975). Predictors of who did (n = 1680) and who did not (n = 295) have surgery were analyzed using multivariate logistic regression.

RESULTS: Participants (n = 1975; 42.4% response rate) were primarily women (84%) and either non-Hispanic Black or Hispanic (60%). In the fully adjusted multivariate model, the strongest predictors of having surgery were being a woman (OR = 3.17; 95% CI = 2.15, 4.68; p < .001) and losing at least 5% of their body weight in the year before surgery (OR = 3.16; 95% CI = 2.28, 4.38; p < .001). The strongest predictors of not having surgery were a BMI 50 kg/m2 (OR = .39; 95% CI = .27, .56; p < .001) and having a higher physical comorbidity burden (OR = .84; 95% CI = .75, .94; p = .004).

CONCLUSIONS: Practices such as 5-10% total weight loss before surgery and selection of patients with safer operative risk profiles (younger with lower comorbidity burden) may inadvertently contribute to under-utilization of bariatric surgery among some demographic subpopulations who could most benefit from this intervention.

PMID:33125675 | DOI:10.1007/s11695-020-05045-7

The rest is here:
The Bariatric Experience Long Term (BELONG): Factors Related to Having Bariatric Surgery in a Large Integrated Healthcare System - DocWire News

Savvy Senior:How to recognize and stop elder abuse in the COVID era

Dear Savvy Senior,

Can you write a column on how to recognize elder abuse and what to do if you suspect it?

Concerned Relative

Dear Concerned,

Elder abuse is a big problem in the United States that has escalated during the COVID-19 pandemic. According to the National Council on Aging, as many as 5 million seniors are victims of abuse each year, but studies suggest this crime is significantly under-reported. Only 1-in-14 cases of elder abuse ever get reported to the authorities because victims are usually too afraid, too embarrassed, too helpless or too trusting to call for help.

The term elder abuse is defined as intentional or negligent acts by a caregiver or trusted individual that causes or can cause harm to a vulnerable senior. Elder abuse also comes in many different forms: emotional, psychological, physical or sexual abuse, abandonment, neglect and self-neglect, and financial exploitation.

Those most vulnerable are seniors that are ill, frail, disabled, socially isolated or mentally impaired due to dementia or Alzheimers disease.

Its also important to know that while elder abuse does happen in nursing homes and other long-term care facilities, the vast majority of incidents take place at home where the senior lives. And tragically, the abusers are most often their own family members (usually the victims adult child or spouse) or caregiver.

How to Recognize Abuse

So, how can you tell if an elderly relative or friend is being abused, and what can you do to help?

A change in general behavior is a universal warning sign that a problem exists. If you notice that your relative or friend has become very depressed, withdrawn or gets upset or agitated easily, you need to start asking questions. Here are some additional warning signs on the different types of elder abuse that can help you spot a possible problem.

Physical or sexual abuse: Suspicious bruises or other injuries that cant be explained. Sudden changes in behavior (upset, withdrawn, fearful). Broken eyeglasses. Caregivers refusal to allow visitors to see an elder alone.

Neglect or self-neglect: Weight loss, poor hygiene, unattended medical needs, and unsanitary, unsafe living conditions.

Emotional or psychological abuse: The senior is extremely upset, agitated, withdrawn, unresponsive, fearful or depressed, or demonstrates some other unusual behavior.

Financial exploitation: Missing money or valuables. Unexplained withdrawals from bank accounts, or transfers between accounts. Unauthorized use of credit, debit or ATM card. Unpaid bills despite available funds. Checks written as a loan or gift. Abrupt changes in a will or other documents.

For more tips on how to recognize the warning signs of abuse during the pandemic, see the National Center on Elder Abuse website at NCEA.acl.gov/Resources/COVID-19.aspx.

What to Do

The best ways to help stop elder abuse is to be in touch and keep the lines of communication open. If you suspect any type of abuse or neglect in your relatives or friends home, report it to your local protective services agency.

Adult Protective Services is the government agency responsible for investigating elder abuse cases and providing help and guidance. Call the Eldercare Locator at 800-677-1116 to get the agency contact number in your area or visit NCEA.acl.gov/Resources/State.aspx.

The agency will ask what you observed, who was involved, and who they can contact to learn more. You dont need to prove that abuse is occurring; it is up to the professional.

Or, to report suspected abuse in a nursing home or assisted living facility, call the local Long-Term Care Ombudsman see LTCombudsman.org for contact information.

If, however, you feel the person is in immediate danger, call 911 or the local police for immediate help.

Send your senior questions to: Savvy Senior, P.O. Box 5443, Norman, OK 73070, or visit SavvySenior.org. Jim Miller is a contributor to the NBC Today show and author of The Savvy Senior book.

See the original post:
Savvy Senior: How to recognize and stop elder abuse in the COVID era - Huron Daily Tribune

By Dr. Havya Dave and Karen Holdsworth, NPProvided by Sentara Northern Virginia Medical Center

Women have particular health-care needs, which often means multiple appointments with different providers. But the female team of providers at Sentara Internal Medicine Physicians in Woodbridge has set out to give women an experience that meets their needs.

Havya Dave, M.D. and Karen Holdsworth, NP understand that women have different needs and many demands placed on them. The duo has worked to establish a practice where women can get much of their care in one location, at one visit.

Most people, but particularly women, talk more openly with their primary care provider since they have a rapport, says Holdsworth. Its easier for us to provide holistic care because we have the time to build a trusting relationship where people open up about their concerns.

We created a practice that allows us to do more for our female patients, says Holdsworth. Women are pulled in so many different directions. We make it easier for them to receive whatever services they need in a single visit, whenever possible. This approach promotes continuity of care because we see the big health picture.

This team of providers eliminates the burden of having to make multiple appointments in different places to take care of health needs.

The team sees females from ages 13 and up. In addition to typical primary care services, they offer:

Preventive gynecologic care can help identify and treat precancerous cells before problems start. The team offers Pap tests and pelvic exams as part of the annual exam. They also perform surgical removal of uterine polyps. And they provide biopsies of the uterine lining to help diagnose bleeding and other problems.

One of the most common concerns women have is related to menstruation, says Dr. Dave. We help women who experience every degree of bleeding, period pain and cycle-related mood swings.

The providers also support women who are pre- or postmenopausal. Holdsworth notes, We address all of the issues that come with menopause, so we can improve womens quality of life.

Our goal is to create an environment where women of all ages can talk about their sexual concerns or ask questions, says Dr. Dave. We offer judgment-free advice and provide contraception services that meet a womans specific situation.

The practice offers prevention and treatment services for sexually transmitted infections, plus contraceptive services, including:

Women who experience incontinence can get early care. The team helps women understand their options, counsels on Kegel exercises and prescribes medications. And they offer cleaning and replacement services for women who have a pessary.

Weight management isnt unique to women, but women think about and process weight concerns differently than men, says Holdsworth. We offer sustainable weight loss advice that includes nutrition and exercise counseling. We dont offer fad, get-thin-quick diets because we know they dont work long-term.

Our environment supports women, says Holdsworth. We want women to feel they arent alone and that their concerns are normal. When they feel supported, they are more at ease and have improved quality of life.

The providers believe that by helping women, theyre helping those around them. Women are the lifeblood of happy, healthy households. When we improve the quality of life for women, we help entire families function better, says Dr. Dave.

Both providers accept new patients at Sentara Internal Medicine Physicians, located at 2280 Opitz Blvd., Suite 250, Woodbridge. Make an appointment by calling 703-523-9750.

Original post:
Female Care Team Understands the Unique Needs of Women - Prince William Living

If youre not incorporating weight training into your workouts, you should consider working it in them now. You may thank yourself later.

Lifting weights isnt just about bulking up and building muscle mass. Its other benefits include improved posture, better sleep, gaining bone density, maintaining weight loss, boosting metabolism, lowering inflammation and staving off chronic disease, to name a few things on the laundry list of positives.

Ask the average person to design an effective fitness plan and a lot of them will immediately go to cardio: walking, running, swimming and using the gyms machines. And while these methods can be effective in burning calories, they may not do enough to build lean muscle capable of improving athletic performance and boosting the metabolism.

Thats why the most effective fitness plans need to include lifting weights and a commitment to strength training. It doesnt mean you have to pump 50-pound dumbbells or spend your whole trip to the gym at the weight machines, but it does mean there has to be some investment of your time and energy toward training with weights.

Lets take a look at the main reason to add weight training to your exercise regimen: it can add years to your life.

Thats because muscle mass plays an important part in determining how we age, and that increased muscle capacity can help us reduce our overall risk of death. In fact, as we age, the focus on losing fat or maintaining weight becomes progressively less important as we progress toward prioritizing keeping the muscle mass and strength we have.

We do so much to improve our overall health but we dont always think about how our exercise regimen affects our long term. For young and middle-aged people, the fitness goal is usually to look and feel better both today and in the near future (perhaps even decades down the road). But the 75-year-old version of you, the one enjoying retirement and spending time with the grandchildren, may be really pleased that the younger edition of you made a commitment to strength training and lifting weights.

Mike Gartz is a personal trainer who owns I Hate My Trainer at 117 E. Reynolds St. Plant City.

Related Stories

Here is the original post:
Focus on Fitness: There's more to lifting weights than meets the eye - Plant City Observer

Page 55«..1020..54555657..6070..»

Home » Long Term Weight Loss » Page 55